Lead Plaintiff Deadline: 05/25/2020
SUMMARY OF CASE:
A securities class action has been filed against AnaptysBio, Inc. (ANAB) on behalf of all investors who purchased or otherwise acquired AnaptysBio common stock between October 10, 2017 and November 7, 2019. This case has been filed in the USDC – S.D.Cal.
The Complaint alleges that throughout the Class Period, the Company touted the prospects of etokimab and the drug’s efficacy based on clinical trial data. In truth, however, the Company failed to disclose key information from the trials and used questionable analysis which made the trial results regarding etokimab’s efficacy and its prospects appear far better than they were. As a result of Defendants’ material misrepresentations and omissions, shares of AnaptysBio’s common stock traded at artificially inflated prices during the Class Period.